Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 04, 2016 | Vice President Finance | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | -- | |
| Dec 03, 2015 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | -- | |
| Sep 21, 2015 | Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 12,584 | -- | -- | |
| Sep 21, 2015 | Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 417 | -- | -- | |
| Jul 14, 2015 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 142,250 | -- | -- | |
| Jul 13, 2015 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | -- | |
| Jul 13, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 9,500 | -- | -- | |
| Jun 23, 2015 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 55,000 | $14.01 | -- | |
| Jun 23, 2015 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | -- | |
| Jun 23, 2015 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 15,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.